Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions

Movement Disorders

Volumn 30, Issue 14, 2015, Pages 1862-1869

  Jankovic, Joseph ^a   Bressman, Susan ^b   Dauer, William ^c   Kang, Un Jung ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Dystonia; Myoclonus; Parkinson's disease; Tardive dyskinesia; Tics; Tremor

Indexed keywords

ALPHA TOCOPHEROL; BOTULINUM TOXIN; LEVODOPA; SELEGILINE; TRIHEXYPHENIDYL;

BRAIN DEPTH STIMULATION; CHOREA; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; DYSTONIA; HUMAN; HYPERKINESIA; MOTOR DYSFUNCTION; MULTICENTER STUDY (TOPIC); MYOCLONUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEREOTYPY; TARDIVE DYSKINESIA; TIC; TREMOR; MOVEMENT DISORDERS; RESEARCH;

HUMANS; MOVEMENT DISORDERS; RESEARCH;

EID: 84955179896     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26445     Document Type: Review

References (78)

1. Fahn S, Elton RL, members of the UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, New Jersey: Macmillan Healthcare Information; 1987:153-163, 293-304.
2. Hornykiewicz O. A brief history of levodopa. J Neurol 2010;257:S249-S252.
3. Fahn S, Libsch LR, Cutler RW. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971;14:427-455.
4. Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson's disease and a pilot trial of high-dosage antioxidants in an attempt to slow the progression of the illness. Ann N Y Acad Sci 1989;570:186-196.
5. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
6. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
7. Parkinson Study Group. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord 2013;28:1823-1831.
8. Goldberg JA, Guzman JN, Estep CM et al. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat Neurosci 2012;15:1414-1421.
9. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812.
10. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 2013;3:461-491.
11. Surmeier DJ, Schumacker PT. Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease. J Biol Chem 2013;288:10736-10741.
12. Dehay B, Bourdenx M, Gorry P, et al. Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol 2015;14:855-866.
13. Dauer W, Kholodilov N, Vila M, et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A 2002;99:14524-14529.
14. LaVoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG. The effects of oxidative stress on parkin and other E3 ligases. J Neurochem 2007;103:2354-2368.
15. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol 1992;32 Suppl:S128-S132.
16. Fahn S, Chouinard S. Experience with tranylcypromine in early Parkinson's disease. J Neural Transm Suppl 1998;52:49-61.
17. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
18. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
19. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
20. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-1278.
21. Fitzmaurice AG, Rhodes SL, Cockburn M, Ritz B, Bronstein JM. Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease. Neurology 2014;82:419-426.
22. Zhuang X, Mazzoni P, Kang UJ. The role of neuroplasticity in dopaminergic therapy for Parkinson disease. Nat Rev Neurol 2013;9:248-256.
23. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(Suppl 4):IV37-IV42.
24. Brundin P, Pogarell O, Hagell P, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000;123(Pt 7):1380-1390.
25. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
26. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
27. Barker RA, Drouin-Ouellet J, Parmar M. Cell-based therapies for Parkinson disease: past insights and future potential. Nat Rev Neurol 2015;11:492-503.
28. Fahn S. The varied clinical expressions of dystonia. Neurol Clin 1984;2:541-554.
29. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-1346.
30. Burke RE, Fahn S, Gold AP. Delayed-onset dystonia in patients with "static" encephalopathy. J Neurol Neurosurg Psychiatry 1980;43:789-797.
31. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985;35:73-77.
32. Burke RE, Fahn S, Marsden CD. Torsion dystonia: a double-blind, prospective trial of high-dosage trihexyphenidyl. Neurology 1986;36:160-164.
33. Ozelius LJ, Hewett JW, Page CE, et al. The earlyonset torsion dystonia gene (DYT1) encodes an ATP binding protein. Nat Genet 1997;17:4048.
34. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;28:863-873.
35. Dobyns WB, Ozelius LJ, Kramer PL, et al. Rapid-onset dystonia parkinsonism. Neurology 1993;43:2596-2602.
36. Brashear A, Dobyns W, de Carvalho Aguiar P, et al. The phenotypic spectrum of rapid-onset dystonia: parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007;130:828-835.
37. Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B et al. De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet 2012;44:1030-1034.
38. Li M, Jazayeri D, Corry B, et al. A functional correlate of severity in alternating hemiplegia of childhood. Neurobiol Dis 2015;77:88-93.
39. Wijemanne S, Jankovic J. Dopa-responsive dystonia-clinical and genetic heterogeneity. Nat Rev Neurol 2015;11:414-424.
40. Hully M, Vuillaumier-Barrot S, Le Bizec C, et al. From splitting GLUT1 deficiency syndromes to overlapping phenotypes. Eur J Med Genet 2015;58:443-454.
41. Teive HA, Moro A, Moscovich M, et al. Ataxia-telangiectasia: a historical review and a proposal for a new designation: ATM syndrome. J Neurol Sci 2015;355:3-6.
42. Liang CC, Tanabe LM, Jou S, Chi F, Dauer WT. TorsinA hypofunction causes abnormal twisting movements and sensorimotor circuit neurodegeneration. J Clin Invest 2014;124:3080-3092.
43. Jankovic J. Medical treatment of dystonia. Mov Disord 2013;28:1001-1012.
44. Jinnah HA, Teller JK, Galpern WR. Recent developments in dystonia. Curr Opin Neurol 2015;28:400-405.
45. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-254.
46. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616-623.
47. Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics 2014;11:139-152.
48. Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 2014;90:344-348.
49. Panov F, Gologorsky Y, Connors G, et al. Deep brain stimulation in DYT1 dystonia: a 10-year experience. Neurosurgery 2013;73:86-93.
50. Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol 2014;13:875-884.
51. Fox MD, Alterman RL. Brain stimulation for torsion dystonia. JAMA Neurol 2015;72:713-719.
52. Slotty PJ, Poologaindran A, Honey CR. A prospective, randomized, blinded assessment of multitarget thalamic andpallidal deep brain stimulation in a case of hemidystonia. Clin Neurol Neurosurg 2015;138:16-19.
53. Shaikh AG, Mewes K, DeLong MR, et al. Temporal profile of improvement of tardive dystonia after globus pallidus deep brain stimulation. Parkinsonism Relat Disord 2015;21:116-119.
54. Cheung T, Noecker AM, Alterman RL, McIntyre CC, Tagliati M. Defining a therapeutic target for pallidal deep brain stimulation for dystonia. Ann Neurol 2014;76:22-30.
55. Meoni S, Zurowski M, Lozano AM, Hodaie M, Poon YY, Fallis M, et al. Long-term neuropsychiatric outcomes after pallidal stimulation in primary and secondary dystonia. Neurology 2015;85:433-40.
56. Brüggemann N, Kühn A, Schneider SA, et al. Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia. Neurology 2015;84:895-903.
57. Jankovic J, Fahn S. Physiologic and pathological tremors: Diagnosis, mechanism and management. Ann Intern Med 1980;93:460-465.
58. Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: phenomenology, etiology, and treatment. Mov Disord. 2015;30:171-179.
59. Fahn S, Tolosa E, Martin C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore: Urban and Schwarzenberg; 1988:225-234.
60. Elble R, Comella C, Fahn S, et al. Reliability of a new scale for essential tremor. Mov Disord 2012;27:1567-1569.
61. Elias WJ, Shah BB. Tremor. JAMA 2014;311:948-954.
62. Frucht SJ, Leurgans SE, Hallett M, Fahn S. The Unified Myoclonus Rating Scale. Adv Neurol 2002;89:361-376.
63. Jankovic J. Therapeutic developments for tics and myoclonus. Mov Disord 2015;30:1566-1573.
64. Jankovic J, Fahn S. The phenomenology of tics. Mov Disord 1986;1:17-26.
65. Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol 2014;13:100-112.
66. Hirschtritt ME, Lee PC, Pauls DL, et al., for the Tourette Syndrome Association International Consortium for Genetics. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry 2015;72:325-333.
67. Fahn S. Treatment of tardive dyskinesia: use of dopaminedepleting agents. Clin Neuropharmacol 1983;6:151-158.
68. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Exp Rev Neurother 2011;11:1509-1523.
69. Müller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Exp Opin Invest Drugs 2015;24:737-742.
70. Jankovic J. "Psychogenic" versus "functional" movement disorders? That is the question. Mov Disord 2014;29:1697-1698.
71. Fahn S, Williams DT. Psychogenic dystonia. Dystonia 2. Adv Neurol 1988;50:431-455.
72. Thenganatt MA, Jankovic J. Psychogenic movement disorders. Neurol Clin 2015;33:205-224.
73. Fuchs T, Gavarini S, Saunders-Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 2009;41:286-288.
74. Xiao J, Uitti RJ, Zhao Y, et al. Mutations in CIZ1 cause adult onset primary cervical dystonia. Ann Neurol 2012;71:458-469.
75. Charlesworth G, Plagnol V, Holmström KM, et al. Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis. Am J Hum Genet 2012;91:1041-1050.
76. Fuchs T, Saunders-Pullman R, Masuho I, et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet 2013;45:88-92.
77. Zech M, Lam DD, Francescatto L, et al. Recessive mutations in the α3 (VI) collagen gene COL6A3 cause early-onset isolated dystonia. Am J Hum Genet 2015;96:883-893.
78. Charlesworth G, Angelova PR, Bartolomé-Robledo F, et al. Mutations in HPCA cause autosomal-recessive primary isolated dystonia. Am J Hum Genet 2015;96:657-665.